

This document is intended as a guideline only and should not replace sound clinical judgment

Table 1: Reversal for ANTICOAGULANT therapy

ANTITHROMBOTIC	REVERSAL AGENT	COMMENTS
DIRECT THROMBIN INHIBITORS (DTIs)	Short half-life and discontinuation of DTI are primary means of attenuating bleed – support with crystalloid and blood products to facilitate rapid renal clearance of drug	<u>Off-label use of</u> <u>rFVIIa/PCC</u> :
IV:	4 Factor PCC	- REQUIRES ATTENDING APPROVAL
 Argatroban 	Dose*: 50 units/kg (dose cap at 100 kg to mitigate thrombotic risk)	 Document attending
– Bivalirudin	Administration: Place in empty IV bag and give slow IV push over 10 minutes	name in the order
(Angiomax [®])	 Use within 4 hours of reconstitution 	comments
Half-life 10-90	<u>Onset</u> : <30 minutes	
minutes	<u>Caution</u> : thrombotic risk	Additional options:
PO:		 If dabigatran ingested
– Dabigatran		within 1 hour, consider
(Pradaxa®)	rFVIIa	activated charcoal.
Half-life 12-17	Dose*: 100 mcg/kg (dose cap at 100 kg to mitigate thrombotic risk)	 Mechanical methods,
hours in normal	 May repeat in 2 hours if continued bleeding Administration 10 (holes over 2.5 minutes) 	such as dialysis, may be
renal function	Administration: IV bolus over 3-5 minutes	considered as a last
	 Use within 3 hours of reconstitution 	resort
The aPTT is currently	Onset: <30 minutes	
the only readily	<u>Caution</u> : thrombotic risk	Recommend not giving
available lab test to		rFVIIa and PCC together
QUALITATIVELY		due to high risk of
measure dabigatran.		thrombosis unless clinical
Do not use PT/INR		situation warrants
FACTOR XA	4 Factor PCC	<u>Off-label use of</u>
INHIBITORS	Dose*: 50 units/kg (dose cap at 100 kg to mitigate thrombotic risk)	<u>rFVIIa/PCC</u> :
 Fondaparinux 	Administration: Place in empty IV bag and give slow IV push over 10 minutes	– REQUIRES ATTENDING
(Arixtra®)	 Use within 4 hours of reconstitution 	APPROVAL
Half-life 17-21	Onset: <30 minutes	 Document attending
hours in normal	<u>Caution</u> : thrombotic risk	name in the order
renal function		comments
– Rivaroxaban		
(Xarelto [®])		
Half-life 5-9 hours	rFVIIa	Additional option:
(up to 13 hours in	Dose*: 100 mcg/kg (dose cap at 100 kg to mitigate thrombotic risk)	If rivaroxaban, apixaban or
elderly) – Apixaban	 May repeat in 2 hours if continued bleeding Administration: IV bolus over 3-5 minutes 	edoxaban ingested within 1 hour, consider activated
(Eliquis [®])	– Use within 3 hours of reconstitution	charcoal
Half-life 8-15	Onset: <30 minutes	charcoar
hours	<u>Caution</u> : thrombotic risk	Recommend not giving
– Edoxaban		rFVIIa and PCC together
(Savaysa [®])		due to high risk of
Half-life 10-14		thrombosis unless clinical
hours)		situation warrants
•		
The PT and the		
UFH/LMWH anti-		
Factor XA assay are		
currently the only		
readily available		
labs test to		
QUALITATIVELY		
measure		
rivaroxaban,		
apixaban or		
edoxaban.		
Do not use INR.		

HEPARIN	Protamine	Prophylactic SQ doses of		
Half-life: 1-2 hours	Dose: 1 mg reverses 100 units of UFH		UFH do not lead to	
	Time since UFH Dose per 100units UFH over last 3h		increased risk of	
	<30 min	1 mg	hemorrhage. Look for	
	30-120 min	0.5 mg	other causes of	
	>120 min	0.25 mg	hemorrhage	
		 Do not exceed 50mg in a single dose; high doses can have an undesirable 		
	ANTIcoagulant effect			
	 In clinical practice, give 50 mg IV x1 over 1 			
	continues.			
	Administration: Slow IV push not to exceed 5			
	Onset: 5-15 minutes			
	<u>Caution</u> : Rapid administration can cause seve			
LMWHs	Protamine (Does not reverse LMWH as effectiv	•	If aPTT remains	
(enoxaparin)	Dose: 1 mg for each 1 mg of enoxaparin in las		prolonged, may give 2nd	
Half-life: 2-8 hours	 If >12 hrs have elapsed since LMWH admir 	dose of 0.5mg protamine		
	 Do not exceed 50mg in a single dose; high 	per 1 mg LMWH		
	ANTIcoagulant effect			
	 In clinical practice, give 50 mg IV x1 over 1 	10 minutes. May redose if bleeding	Consider FFP and other	
	continues.		blood product support.	
	Administration: Slow IV push not to exceed 5			
	<u>Onset</u> : 5-15 minutes			
	Caution: Rapid administration can cause seve	re hypotension and anaphylaxis		
WARFARIN	SUPRATHERAPEUTIC INR	Phytonadione (Vitamin K)	<u>Off-label use of</u>	
Half-life 36 hours	INR 5-9: Omit 1-2 warfarin doses	<u>Dose</u> : See box on left	<u>rFVIIa/PCC</u> :	
(5 days for INR	± 1-2.5mg PO Vit K	Administration: IV- dilute in 50 ml NS	– REQUIRES ATTENDING	
normalization)	INR > 9 (NO BLEED): omit 1-2 warfarin	and give over 30 minutes	APPROVAL	
	doses ± 2.5-5mg PO Vit K	Onset: PO=24 hours; IV=12 hours	 Document attending 	
	ACTIVE BLEEDING AT ANY INR:	Caution: IV - may be associated with	name in the order	
	 Hold warfarin & give Vit K 5-10mg IV 	very small risk of anaphylaxis	comments	
	(may repeat q12h) PLUS either PCC or FFP	FFP		
	(PCC is PREFERRED)	<u>Dose</u> : See box on left	ROUND DOSE TO NEAREST	
		Administration: At least 10 ml/min	WHOLE VIAL	
	4 Factor PCC 25 units/kg if INR >1.7 -<4*	<u>Onset</u> : 2-6 hours		
	4 Factor PCC 35 units/kg if INR 4-6*	Caution: Carries risk of infection, must		
	4 Factor PCC 50 units/kg if INR > 6*	be thawed and a large volume is	REPEAT INR 30 MINUTES	
	(dose cap at 100 kg to mitigate thrombotic	required (often > 1 liter)	AFTER END OF PCC	
	risk)	PCC	INFUSION.	
	OR	<u>Dose</u> : See box on left		
	 FFP 10-30 mL/kg 	Administration: Place in empty IV bag		
		and give slow IV push over 10	may consider repeat PCC	
	SURGERY REVERSAL	minutes	dose if INR target not	
	■ INR > 1.5-2.5	 Use within 4 hours of 	achieved	
	Surgery <24 hours: 0.5-1mg IV Vit K x1	reconstitution		
	<u></u>	<u>Onset</u> : <30 minutes		
	Surgery 24-96 hours: 0.5-1mg PO Vit K x1	Caution: thrombotic risk		
	monitor INR g12-24h			
	■ INR >2.5-5			
	<u>Surgery <24 hours</u> : 1-2.5mg IV Vit K x1 +/- 5-8mL/kg FFP			
	Surgery 24-96 hours: 1-2.5mg PO Vit K x1			
	monitor INR q12-24h arin, PCC = prothrombin complex concentrates (Bebulin			

UFH=unfractionated heparin, PCC = prothrombin complex concentrates (Bebulin), FFP = fresh frozen plasma, rVIIa = recombinant active factor VIIa (NovoSeven), DDAVP = desmopressin, SIVP = slow intravenous push, LMWH=low molecular weight heparin

*Denotes that doses are NOT based on high quality evidence

Consider the following agents, along with ROTEM testing, if patient refractory to standard therapies:

DDAVP

Mechanism: increases release of vWF and enhances platelet adhesion and aggregation

Dose: 0.3 mcg/kg in 50 ml NS IV over 15 minutes

Caution: Serial doses associated with tachyphylaxis, hyponatremia, and seizures

Aminocaproic acid:

Mechanism: antifibrinolytic

<u>Dose</u>: 4-5 gm loading dose in 250 ml NS over 15 minutes followed by infusion of 1gm/hr infusion until bleeding subsides (max 30 gm/day) <u>Caution</u>: May require renal adjustment

Tranexamic acid:

Mechanism: antifibrinolytic

<u>Dose</u>: 1 gm loading dose in 50 ml NS IV over 10 minutes followed by 1 gm in 250 ml NS infused over the next 8 hours <u>Caution</u>: May require renal adjustment


	HALF-LIFE	REVERSAL AGENT	COMMENTS
ASPIRIN	15-30 minutes	DDVAP	May need transfusion of functioning
	5-10 days for platelet	<u>Dose</u> : 0.3 mcg/kg IV x 1	platelets to attenuate bleeding
	recovery	Administration: over 15 minutes	
CLOPIDOGREL	8 hours	Onset: Immediate	
(Plavix®)	~ 5 days for platelet	Caution: Serial doses associated	
	recovery	with tachyphylaxis, hyponatremia,	
PRASUGREL	7 hours	and seizures	
(Effient®)	< 7 days for platelet recovery		
TICAGRELOR	~ 9 hours	-	
(Brilinta®)	3 days for platelet recovery		
Gp IIb-IIIa	30-120 minutes	DDVAP	 Short half-life and discontinuation of
Eptifibatide (Integrilin [®])		Dose: 0.3 mcg/kg IV x 1	gpIIb-IIIa are primary means of
Abciximab (Reopro [®])		Administration: over 15 minutes	attenuating bleed
Tirofiban (Aggrastat [®])		Onset: Immediate	 May need transfusion of functioning
		Caution: Serial doses associated	platelets to attenuate bleeding
		with tachyphylaxis, hyponatremia,	 Mechanical methods, such as dialysis,
		and seizures	may be considered as a last resort

Table 2: Reversal for ANTIPLATELET therapy

UFH=unfractionated heparin, PCC = prothrombin complex concentrates (Bebulin), FFP = fresh frozen plasma, rVIIa = recombinant active factor VIIa (NovoSeven), DDAVP = desmopressin, SIVP = slow intravenous push, LMWH=low molecular weight heparin

*Denotes that doses are NOT based on high quality evidence

OVERALL MANAGEMENT OF ANTICOAGULATED BLEEDING PATIENT



REFERENCES:

- Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI; American College of Chest Physicians. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):141S-159S.
- 2. Levi MM, Eerenberg E, Löwenberg E, Kamphuisen PW. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med. 2010 Feb;68(2):68-76.
- 3. Follis F, Filippone G, Montalbano G, Floriano M, Lobianco E, D'Ancona G, et al. Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative? Interact Cardiovasc Thorac Surg. 2010 Apr;10(4):592-6.Epub 2010 Jan 8.
- Martin ME, Kloecker GH, Laber DA. Argatroban for anticoagulation during cardiac surgery. Eur J Haematol. 2007 Feb;78(2):161-6.
- 5. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006 Jan 18;295(3):293-8.
- 6. Huvers F, Slappendel R, Benraad B, van Hellemondt G, van Kraaij M. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. Neth J Med. 2005 May;63(5):184-6.
- 7. Product Information: CYKLOKAPRON(R) injection, tranexamic acid injection. Pfizer & Upjohn Company, New York, NY, 2008.
- 8. Mathew P, Simon TL, Hunt KE, Crookston, KP. How we manage requests for recombinant factor VIIa (NovoSeven). Transfusion 2007; 47:8-14.
- 9. Peter FW, Benkovic C, Muehlberger T, Vogt PM, Homann HH, Kuhnen C, et al. Effects of desmopressin on thrombogenesis in aspirin-induced platelet dysfunction. Br J Haematol. 2002 Jun;117(3):658-63.
- 10. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994 May 5;330(18):1287-94.
- 11. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood. 2008 May 15;111(10):4871-9. Epub 2008 Feb 28.
- 12. Parakh S, Naik N, Rohatgi N, Bhat U, Parakh K. Eptifibatide overdose. Int J Cardiol. 2009 Jan 24;131(3):430-2. Epub 2007 Nov 19.
- 13. Crowther MA, Berry LR, Monagle PT, Chan AK. Mechanisms responsible for the failure of protamine to inactivate lowmolecular-weight heparin. Br J Haematol 2002;116:178-86.
- 14. Leithäuser B, Zielske D, Seyfert UT, Jung F. Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clin Hemorheol Microcirc. 2008;39(1-4):293-302.
- 15. Ranucci M, Nano G, Pazzaglia A, Bianchi P, Casana R, Tealdi DG. Platelet mapping and desmopressin reversal of platelet inhibition during emergency carotid endarterectomy. J Cardiothorac Vasc Anesth.2007Dec;21(6):851-4.Epub2007 Jul 30.
- 16. Dobesh P. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Pharmacotherapy. 2009Sep;29(9):1089-102.
- 17. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010 Jun;103(6):1116-27.Epub 2010 Mar 29
- 18. Mathew P, Simon TL, Hunt KE, Crookston, KP. How we manage requests for recombinant factor VIIa (NovoSeven). Transfusion 2007; 47:8-14.
- 19. Nowakowski K, Rogers J, Nelson G, Gunalingam B. Abciximab-induced thrombocytopenia: management of bleeding in the setting of recent coronary stents. J Interv Cardiol. 2008 Feb;21(1):100-5. Epub 2008 Jan 13.
- 20. Dobesh PP. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Pharmacotherapy. 2009 Sep;29(9):1089-102.

Originated by: Thomas Dilworth, PharmD; Allison Burnett, PharmD; Isaac Tawil, MD; David Garcia, MD Last reviewed and approved by: UNMH Anticoagulation Subcommittee April 2013